Hikma Pharmaceutical | HIK - Selling And Administration Expenses


Hikma Pharmaceutical reported $288M in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
argenx SE USD 429.62M 93.32M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Autolus Therapeutics Ltd USD 35.79M 1.68M Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Fresenius EUR 819M 143M Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Orion EUR 110.7M 26.1M Dec/2025
Recordati EUR 171.38M 15.6M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.47B 193M Dec/2025